Cannabinoid modulation of peripheral autonomic and sensory neurotransmission

European Journal of Pharmacology

Volumn 472, Issue 1-2, 2003, Pages 1-21

  Ralevic, Vera ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

Anandamide; Cannabinoid; Neurotransmission

Indexed keywords

2 METHYL 3 (1 NAPHTHOYL) 1 PROPYLINDOLE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CAPSAICIN; CLONIDINE; DEXANABINOL; DOPAMINE DERIVATIVE; DRONABINOL; IMIDAZOLINE DERIVATIVE; JWH 051; LIGAND; N ARACHIDONOYLDOPAMINE; N(G) NITROARGININE METHYL ESTER; NEUROTRANSMITTER; NORADRENALIN; OPIATE RECEPTOR AFFECTING AGENT; RAUWOLSCINE; RIMONABANT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR;

AUTONOMIC NERVE; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; BRADYCARDIA; CENTRAL NERVOUS SYSTEM; DRUG ACTIVITY; DRUG EFFECT; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; HEMODYNAMICS; HUMAN; HYPERTENSION; HYPOTENSION; INTESTINE SECRETION; KNOCKOUT MOUSE; NERVE CELL MEMBRANE; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; REVIEW; SCIATIC NERVE; SENSORY NERVE; SMOOTH MUSCLE RELAXATION; STOMACH EMPTYING; SYMPATHETIC NERVE; SYNAPSE VESICLE; TACHYCARDIA; VAS DEFERENS;

EID: 0038305042     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(03)01813-2     Document Type: Review

References (174)

1. Ahluwalia J., Urban L., Capogna M., Bevan S., Nagy I. Cannabinoid receptors are expressed in nociceptive primary sensory neurons. Neuroscience. 100:2000;685-688.
2. Ahluwalia J., Yaqoob M., Urban L., Bevan S., Nagy I. Activation of capsaicin-sensitive primary sensory neurones induces anandamide production and release. J. Neurochem. 84:2003;585-591.
3. Al-Hayani A., Wease K.N., Ross R.A., Pertwee R.G., Davies S.N. The endogenous cannabinoid anandamide activates vanilloid receptors in the rat hippocampal slice. Neuropharmacology. 41:2001;1000-1005.
4. Beltramo M., Piomelli D. Anandamide transport inhibition by the vanilloid agonist olvanil. Eur. J. Pharmacol. 364:1999;75-78.
5. Benowitz N.L., Rosenberg J., Rogers W., Bachman J., Jones R.T. Cardiovascular effects of intravenous delta-9-tetrahydrocannabinol: autonomic nervous mechanisms. Clin. Pharmacol. Ther. 25:1979;440-446.
6. 9-tetrahydrocannabinol in the blood pressure of hypertensive rats bearing regenerated adrenal glands. Br. J. Pharmacol. 48:1973;169-171.
7. 1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem. J. 351:2000;817-824.
8. Bonhaus D.W., Chang L.K., Kwan J., Martin G.R. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J. Pharmacol. Exp. Ther. 287:1998;884-888.
9. Bouaboula M., Perrachon S., Canant X., Rinaldi-Carmona M., Portier M., Barth F., Calandra B., Pecceu F., Lupker J., Maffrand J.-P., Le Fur G., Casellas P. A selective inverse agonist for central cannabinoid receptors inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor: 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem. 272:1997;22330-22339.
10. 2 receptor messenger RNAs during embryonic development in the rat. Neuroscience. 82:1998;1131-1149.
11. 1 receptor-deficient mice. Hypertension. 39:2002;251-257.
12. Burnstock G. Autonomic neuromuscular junctions: current developments and future directions. J. Anat. 146:1986;1-30.
13. Burnstock G. Co-transmission. The fifth Heymans memorial lecture. Arch. Int. Pharmacodyn. Ther. 304:1990;7-33.
14. Burnstock G., Ralevic V. Cotransmission. Garland C.J., Angus J. The Pharmacology of Vascular Smooth Muscle. 1996;210-232 Oxford Univ. Press, Oxford.
15. Butrica J.L. The medicinal use of cannabis among the Greeks and Romans. J. Cannabis Ther. 2:2002;51-70.
16. Caterina M.J., Julius D. The vanilloid receptor: a molecular gateway to the pain pathway. Annu. Rev. Neurosci. 24:2001;487-517.
17. Caterina M.J., Schumacher M.A., Tominaga M., Rosen T.A., Levine J.D., Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature. 389:1997;816-824.
18. Caterina M.J., Leffler A., Malmberg A.B., Martin W.J., Trafton J., Petersen-Zeitz K.R., Koltzenburg M., Basbaum A.I., Julius D. Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science. 288:2000;306-313.
19. Chaytor A.T., Martin P.E.M., Evans W.H., Randall M.D., Griffith T.M. The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. J. Physiol. 520:1999;539-550.
20. Chemin J., Monteil A., Perez-Reyes E., Nargeot J., Lory P. Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J. 20:2001;7033-7040.
21. Christopoulos A., Coles P., Lay L., Lew M.J., Angus J.A. Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens. Br. J. Pharmacol. 132:2001;1281-1291.
22. Coutts A.A., Pertwee R.G. Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus. Br. J. Pharmacol. 121:1997;1557-1566.
23. 2+ and cAMP. Can. J. Physiol. Pharm. 76:1998;340-346.
24. Craib S.J., Ellington H.C., Pertwee R.G., Ross R.A. A possible role of lipoxygenase in the activation of vanilloid receptors by anandamide in the guinea-pig bronchus. Br. J. Pharmacol. 134:2001;30-37.
25. 1 receptors in human ileum. Br. J. Pharmacol. 125:1998;1393-1395.
26. Davis J.B., Gray J., Gunthorpe M.J., Hatcher J.P., Davey P.T., Overend P., Harries M.H., Latcham L., Claphams C., Atkinson K., Hughes S.A., Rance K., Grau E., Harper A.J., Pugh P.L., Rogers D.C., Bingham S., Randall A.D., Sheardown S.A. Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature. 405:2000;183-187.
27. DePetrocellis L., Bisogno T., Maccarone M., Dais J.B., Finazzi-Agro A., DiMarzo V. The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J. Biol. Chem. 276:2001;12856-12863.
28. Deutsch D.G., Goligorsky M.S., Schmid P.C., Krebsbach R.J., Schmid H.H.O., Das S.K., Dey S.K., Arreaza G., Thorup C., Stefano G., Moore L.C. Production and physiological actions of anandamide in the vasculature of the rat kidney. J. Clin. Invest. 100:1997;1538-1546.
29. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
30. Di Marzo V. Biosynthesis and inactivation of endocannabinoids: relevance to their proposed role as neuromodulators. Life Sci. 65:1999;645-655.
31. Di Marzo V., Fontana A., Cadas H., Scinelli S., Cimino G., Schwartz J.-C., Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 372:1994;686-691.
32. Di Marzo V., Melck D., Bisogno T., De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 21:1998;521-528.
33. Di Marzo V., Bisogno T., De Petrocellis L., Melck D., Orlando P., Wagner J.A., Kunos G. Biosynthesis and inactivation of the endocannabinoid 2-arachidonoylglycerol in circulating and tumoral macrophages. Eur. J. Biochem. 264:1999;258-267.
34. Di Marzo V., Blumberg P.M., Szallasi A. Endovanilloid signaling in pain. Curr. Opin. Neurobiol. 12:2002;372-379.
35. Duncan M., Kendall D.A., Ralevic V. Effect of WIN55,212, a cannabinoid receptor agonist, on sensory neurotransmission in the rat isolated mesenteric arterial bed. Br. J. Pharmacol. 135:2001;65P.
36. 1-like receptors in the rat isolated mesenteric arterial bed. Br. J. Pharmacol. 135:2002;285P.
37. 9-Tetrahydrocannabinol attenuates sensory neurotransmission in the rat isolated mesenteric arterial bed. Br. J. Pharmacol. 2003;. (in press).
38. Ellis J.L., Burnstock G. Angiotensin modulation of adrenergic and purinergic cotransmission in the guinea-pig vas deferens. Br. J. Pharmacol. 97:1989;1157-1164.
39. Elphick M.R., Egertová M. The neurobiology and evolution of cannabinoid signalling. Philos. Trans. R. Soc. Lond., B. 356:2001;381-408.
40. Filippelli A., Falciani M., Piucci B., D'Amico M., D'Agostino B., Filippelli W., Rossi F. Endothelin-1 affects capsaicin-evoked release of neuropeptides from rat vas deferens. Eur. J. Pharmacol. 364:1999;183-191.
41. Fredericks A.B., Benowitz N.L., Savanapridi C.Y. The cardiovascular and autonomic effects of repeated administration of Δ-9-tetrahydrocannabinol to rhesus monkeys. J. Pharmacol. Exp. Ther. 216:1981;247-253.
42. Fuentes J.A., Ruiz-Gayo M., Manzanares J., Vela G., Reche I., Corchero J. Cannabinoids as potential new analgesics. Life Sci. 65:1999;675-685.
43. Gaoni Y., Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J. Am. Chem. Soc. 86:1964;1646-1647.
44. Gardiner S.M., March J.E., Kemp P.A., Bennett T. Complex regional haemodynamic effects of anandamide in conscious rats. Br. J. Pharmacol. 135:2002;1889-1896.
45. 1 receptor antagonist, AM 251, on the regional haemodynamic effects of WIN-55212-2 or HU 210 in conscious rats. Br. J. Pharmacol. 136:2002;581-587.
46. Gauldie S.D., McQueen D.S., Pertwee R., Chessell I.P. Anandamide activates peripheral nociceptors in normal and arthritic rat knee joints. Br. J. Pharmacol. 132:2001;617-621.
47. Giuffrida A., Bletramo M., Piomelli D. Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J. Pharmacol. Exp. Ther. 298:2001;7-14.
48. 3H]noradrenaline from mouse cultured sympathetic neurons: release-modulating heteroreceptors. J. Neurochem. 75:2000;2087-2094.
49. Gonsiorek W., Lunn C., Fan X., Narula S., Lundell D., Hipkin R.W. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Mol. Pharmacol. 57:2000;1045-1050.
50. 2-like cannabinoid receptors on peripheral nerve terminals. Eur. J. Pharmacol. 339:1997;53-61.
51. 1 receptor. Proc. Natl. Acad. Sci. U. S. A. 98:2001;3662-3665.
52. Harris D., McCulloch A.I., Kendall D.A., Randall M.D. Characterization of vasorelaxant responses to anandamide in the rat mesenteric arterial bed. J. Physiol. 539:2002;893-902.
53. Hayes P., Meadows H.J., Gunthorpe M.J., Harries M.H., Duckworth M.D., Cairns W., Harrison D.C., Clarke C.E., Ellington K., Prinjha R.K., Barton A.J.L., Medhurst A.D., Smith G.D., Topp S., Murdock P., Sanger G.J., Terrett J., Jenkins O., Benham C.D., Randall A.D., Gloger I.S., Davis J.B. Cloning and functional expression of a human orthologue of rat vanilloid receptor-1. Pain. 88:2001;207-212.
54. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiography study. J. Neurosci. 11:1991;563-583.
55. Himmi T., Perrin J., Ouzzani T.E., Orsini J.-C. Neuronal responses to cannabinoid receptor ligands in the solitary tract nucleus. Eur. J. Pharmacol. 359:1998;49-54.
56. Hirst G.D.S., Choate J.K., Cousins H.M., Edwards F.R., Klemm M.F. Transmission by post-ganglionic axons of the autonomic nervous system: the importance of the specialized neuroeffector junction. Neuroscience. 73:1996;7-23.
57. Hohmann A.G. Spinal and peripheral mechanisms of cannabinoid antinociception: behavioural, neurophysiological and neuroanatomical perspectives. Chem. Phys. Lipids. 121:2002;173-190.
58. Hohmann A.G., Herkenham M. Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study. Neuroscience. 90:1999;923-931.
59. Hohmann A.G., Herkenham M. Cannabinoid receptors undergo axonal flow in sensory nerves. Neuroscience. 92:1999;1171-1175.
60. Holzer P. Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol. Rev. 43:1991;143-201.
61. Holzer P. Peptidergic sensory neurons in the control of vascular functions: mechanisms and significance in the cutaneous and splanchnic vascular beds. Rev. Physiol. Pharmacol. 121:1992;49-146.
62. Holzer P. Neural injury, repair, and adaptation in the GI tract: II. The elusive action of capsaicin on the vagus nerve. Am. J. Physiol. 275:1998;G8-G13.
63. Howlett A.C., Barth F., Bonner T.I., Cabral G., Casellas P., Devane W.A., Felder C.C., Herkenham M., Mackie K., Martin B.R., Mechoulam R., Pertwee R.G. International Union of Pharmacology: XXVII. Classification of cannabinoid receptors. Pharmacol. Rev. 54:2002;161-202.
64. Huang S.M., Bisogno T., Trevisani M., Al-Hayani A., De Petrocellis L., Fezza F., Tognetto M., Petros T.J., Krey J.F., Chu C.J., Miller J.D., Davies S.N., Gepetti P., Walker M., Di Marzo V. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc. Natl. Acad. Sci. U. S. A. 99:2002;8400-8405.
65. Huestis M.A., Sampson A.H., Holicky B.J., Henningfield J.E., Cone E.J. Characterisation of the absorption phase of marijuana smoking. Clin. Pharmacol. Ther. 52:1992;31-41.
66. Hwang S.W., Cho H., Kwak J., Lee S.-Y., Kang C.-J., Jung J., Cho S., Min K.H., Suh Y.-G., Kim D., Oh U. Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc. Natl. Acad. Sci. U. S. A. 97:2000;6155-6160.
67. 1 receptors on peripheral sympathetic nerves. Br. J. Pharmacol. 118:1996;2023-2028.
68. 2+-induced relaxation. J. Pharmacol. Exp. Ther. 289:1999;245-250.
69. 1 receptors. Br. J. Pharmacol. 124:1998;1363-1368.
70. Izzo A.A., Mascolo N., Capasso F. The gastrointestinal pharmacology of cannabinoids. Curr. Opin. Pharmacol. 1:2001;597-603.
71. Jacobsson S.O.P., Wallin T., Fowler C.F. Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids relative involvement of cannabinoid and vanilloid receptors. J. Pharmacol. Exp. Ther. 299:2001;951-959.
72. 9-tetrahydrocannabinol in conscious and morphine-chloralose-anesthetised dogs: anesthetic influence on drug action. Eur. J. Pharmacol. 53:1978;63-68.
73. 2 receptors. Proc. Natl. Acad. Sci. U. S. A. 96:1999;14136-14141.
74. Jerman J.C., Brough S.J., Prinjha R., Harries M.H., Davis J.B., Smart D. Characterization using FLIPR of rat vanilloid receptor (rVR1) pharmacology. Br. J. Pharmacol. 130:2000;916-922.
75. Jung J., Hwang S.W., Kwak J., Lee S.-Y., Kang C.-J., Kim W.B., Kim D., Oh U. Capsaicin binds to the intracellular domain of the capsaicin-activated ion channel. J. Neurosci. 19:1999;529-538.
76. Kawasaki H., Takasaki K., Saito A., Goto K. Calcitonin gene-related peptide acts as a novel vasodilator neurotransmitter in mesenteric resistance vessels of the rat. Nature. 335:1988;165-167.
77. Kreitzer A.C., Regehr W.G. Retrograde signaling by endocannabinoids. Curr. Opin. Neurobiol. 12:2002;324-330.
78. 1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res. 302:2000;73-80.
79. Kunos G., Batkai S. Novel physiologic functions of endocannabinoids as revealed through the use of mutant mice. Neurochem. Res. 26:2001;1015-1021.
80. Lake K.D., Martin B.R., Kunos G., Varga K. Cardiovascular effects of anandamide in anaesthetized and conscious normotensive and hypertensive rats. Hypertension. 29:1997;1204-1210.
81. 1 receptor. Eur. J. Pharmacol. 334:1997;R1-R2.
82. 1 receptors in the rat and mouse. Eur. J. Pharmacol. 391:2000;151-161.
83. 1 receptor knockout mice. Science. 283(5400):1999;401-404.
84. Lynn A.B., Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J. Pharmacol. Exp. Ther. 268:1994;1612-1623.
85. Maccarrone M., Lorenzon T., Bari M., Melino G., Finazzi-Agro A. Anandamide induces apoptosis in human cells via vanilloid receptors - evidence for a protective role of cannabinoid receptors. J. Biol. Chem. 275:2000;31938-31945.
86. 2 receptors. Br. J. Pharmacol. 124:1998;619-622.
87. Maggi C.A., Meli A. The sensory-efferent function of capsaicin-sensitive sensory neurons. Gen. Pharmacol. 19:1988;1-43.
88. Maggi C.A., Giuliani S., Santicioli P., Meli A. Capsaicin-induced inhibition of motility of the rat isolated vas deferens: do multiple neuropeptides mediate the visceromotor effects of capsaicin. J. Auton. Pharm. 7:1987;243-255.
89. Maggi C.A., Chiba T., Giuliani S. Human α-calcitonin gene-related peptide (8-37) as an antagonist of exogenous and endogenous calcitonin gene-related peptide. Eur. J. Pharmacol. 192:1991;85-88.
90. Mailleux P., Vanderhaeghen J.-J. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience. 48:1992;655-668.
91. 1 receptor-mediated inhibition of the neurogenic vasopressor response in the pithed rat. Naunyn-Schmiedeberg's Arch. Pharmacol. 356:1997;197-202.
92. 1 receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 364:2001;233-241.
93. 1 cannabinoid receptors. Br. J. Pharmacol. 134:2001;161-167.
94. Martin R.S., Luong L.A., Welsh N.J., Eglen R.M., Martin G.R., MacLennan S.J. Effects of cannabinoid receptor agonists on neuronally-evoked contractions of urinary bladder tissues isolated from rat, mouse, pig, dog, monkey and human. Br. J. Pharmacol. 129:2000;1707-1715.
95. Matsuda L.A., Bonner T.I., Lolait S.J. Localization of cannabinoid receptor mRNA in rat brain. J. Comp. Neurol. 327:1993;535-550.
96. Mechoulam R., Fride E., Di Marzo V. Endocannabinoids. Eur. J. Pharmacol. 359:1998;1-18.
97. Mezey E., Toth Z.E., Cortright D.N., Arzubi M.K., Krause J.E., Elde R., Guo A., Blumberg P.M., Szallasi A. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human. Proc. Natl. Acad. Sci. U. S. A. 97:2000;3655-3660.
98. Millns P.J., Chapman V., Kendall D.A. Cannabinoid inhibition of the capsaicin-induced calcium response in rat dorsal root ganglion cells. Br. J. Pharmacol. 132:2001;969-971.
99. Molderings G.J., Göthert M. Presynaptic imidazoline receptors mediate inhibition of noradrenaline release from sympathetic nerves in rat blood vessels. Fundam. Clin. Pharmacol. 12:1998;388-397.
100. Molderings G.J., Göthert M. Imidazoline binding sites and receptors in cardiovascular tissue. Gen. Pharmacol. 32:1999;17-22.
101. Molderings G.J., Likungu J., Göthert M. Presynaptic cannabinoid and imidazoline receptors in the human heart and their potential relationship. Naunyn-Schmiedeberg's Arch. Pharmacol. 360:1999;157-164.
102. Morisset V., Ahluwalia J., Nagy I., Urban L. Possible mechanisms of cannabinoid-induced antinociception in the spinal cord. Eur. J. Pharmacol. 429:2001;93-100.
103. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
104. Niederhoffer N., Szabo B. Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. Br. J. Pharmacol. 126:1999;457-466.
105. Niederhoffer N., Szabo B. Cannabinoids cause central sympathoexcitation and bradycardia in rabbits. J. Pharmacol. Exp. Ther. 294:2000;707-713.
106. Ohno-Shosaku T., Maejima T., Kano M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron. 29:2001;729-738.
107. Ohno-Shosaku T., Tsubokawa H., Mizushima I., Yoneda N., Zimmer A., Kano M. Presynaptic cannabinoid sensitivity is a major determinant of depolarization-induced retrograde suppression at hippocampal synapses. J. Neurosci. 22:2002;3864-3872.
108. Olah Z., Karai L., Iadarola M.J. Anandamide activates vanilloid receptor 1 (VR1) at acidic pH in dorsal root ganglia neurons and cells ectopically expressing VR1. J. Biol. Chem. 276:2001;31163-31170.
109. 1 cannabinoid receptor activity. Mol. Pharmacol. 54:1998;1064-1072.
110. Pertwee R.G. The evidence for the existence of cannabinoid receptors. Gen. Pharmacol. 24:1993;811-824.
111. 2 receptors. Pharmacol. Ther. 74:1997;129-180.
112. Pertwee R.G. Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. 6:1999;635-664.
113. Pertwee R.G. Cannabinoids and the gastrointestinal tract. Gut. 48:2001;859-867.
114. Pertwee R.G. Cannabinoid receptors and pain. Prog. Neurobiol. 63:2001;569-611.
115. 1 receptors in mouse urinary bladder. Br. J. Pharmacol. 118:1996;2053-2058.
116. Pertwee R.G., Griffin G. A preliminary investigation of the mechanisms underlying cannabinoid tolerance in the mouse vas deferens. Eur. J. Pharmacol. 272:1995;67-72.
117. Pertwee R.G., Stevenson L.A., Elrick D.B., Mechoulam R., Corbett A.D. Inhibitory effects of certain enantiomeric cannabinoids in the mouse vas deferens and the myenteric plexus preparation of guinea-pig small intestine. Br. J. Pharmacol. 105:1992;980-984.
118. 1 receptors in guinea-pig small intestine. Br. J. Pharmacol. 118:1996;2199-2205.
119. 1 receptors in mouse vas deferens. Eur. J. Pharmacol. 296:1996;169-172.
120. Piomelli D. The ligand that came from within. Trends Pharmacol. Sci. 22:2001;17-19.
121. Premkumar L.S., Ahern G.P. Induction of vanilloid receptor channel activity by protein kinase C. Nature. 408:2000;985-990.
122. Rademacher D.J., Patel S., Hopp F.A., Dean C., Hillard C.J., Seagard J.L. Microinjection of a cannabinoid receptor antagonist into the NTS increases baroreflex duration in dogs. Am. J. Physiol. 284:2003;H1570-H1576.
123. Ralevic V., Kendall D.A. Cannabinoid inhibition of capsaicin-sensitive sensory neurotransmission in the rat mesenteric arterial bed. Eur. J. Pharmacol. 418:2001;117-125.
124. Ralevic V., Kendall D.A. Cannabinoids inhibit pre- and postjunctionally sympathetic neurotransmission in rat mesenteric arteries. Eur. J. Pharmacol. 444:2002;171-181.
125. Ralevic V., Karoon P., Burnstock G. Long-term sensory denervation by neonatal capsaicin treatment augments sympathetic neurotransmission in rat mesenteric arteries by increasing levels of noradrenaline and selectively enhancing postjunctional actions. J. Pharmacol. Exp. Ther. 274:1995;64-71.
126. Ralevic V., Kendall D.A., Zygmunt P.M., Movahed P., Högestätt E.D. Vanilloid receptors on capsaicin-sensitive sensory nerves mediate relaxation to methanandamide in the rat isolated mesenteric arterial bed. Br. J. Pharmacol. 130:2000;1483-1488.
127. Ralevic V., Kendall D.A., Jerman J.C., Middlemiss D.N., Smart D. Cannabinoid activation of recombinant and endogenous vanilloid receptors. Eur. J. Pharmacol. 424:2001;211-219.
128. Ralevic V., Kendall D.A., Randall M.D., Smart D. Cannabinoid modulation of sensory neurotransmission via cannabinoid and vanilloid receptors: roles in regulation of cardiovascular function. Life Sci. 71:2002;2577-2594.
129. Randall M.D., Harris D., Kendall D.A., Ralevic V. Cardiovascular effects of cannabinoids. Pharmacol. Ther. 95:2002;191-202.
130. 1 receptors. Pain. 75:1998;111-119.
131. Rinaldi-Carmona M., Barth F., Héaulme M., Shire D., Calandra B., Congy C., Martinez S., Maruani J., Néliat G., Caput D., Ferrara P., Soubrié P., Brelière J.C., Le Fur G. SR 141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 350:1994;240-244.
132. Ross R.A., Brockie H.C., Fernando S.R., Saha B., Razdan R.K., Pertwee R.G. Comparison of cannabinoid binding sites in guinea-pig forebrain and small intestine. Br. J. Pharmacol. 125:1998;1345-1351.
133. Ross R.A., Coutts A.A., McFarlane S.M., Anavi-Goffer S., Irving A.J., Pertwee R.G., MacEwan D.J., Scott R.H. Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology. 40:2001;221-232.
134. Ross R.A., Gibson T.M., Brockie H.C., Leslie M., Pashmi G., Craib S.J., Di Marzo V., Pertwee R.G. Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br. J. Pharmacol. 132:2001;631-640.
135. Roth S.H. Stereospecific presynaptic inhibitory effect of Δ-9-tetrahydrocannabinol on cholinergic transmission in the myenteric plexus of the guinea-pig. Can. J. Physiol. Pharm. 56:1978;968-975.
136. Saito A., Tomobe Y., Goto K. Effect of capsaicin on smooth muscles of rat vas deferens: involvement of calcitonin gene-related peptide? J. Pharmacol. Exp. Ther. 242:1987;666-672.
137. Schelb V., Göbel I., Khairallah L., Zhou H., Cox S.L., Trendelenburg A.U., Hein L., Starke K. Postnatal development of presynaptic receptors that modulate noradrenaline release in mice. Naunyn-Schmiedeberg's Arch. Pharmacol. 364:2001;359-371.
138. Shire D., Carillon C., Kaghad M., Calandra B., Rinaldi-Carmona M., Le Fur G., Cpaut D., Ferrara P. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J. Biol. Chem. 270:1995;3726-3731.
139. Smart D., Jerman J.C. Anandamide: an endogenous activator of the vanilloid receptor. Trends Pharmacol. Sci. 21:2000;134.
140. Smart D., Gunthorpe M.J., Jerman J.C., Nasir S., Gray J., Muir A.I., Chambers J.K., Randall A.D., Davis J.B. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol. 129:2000;227-230.
141. Smart D., Jerman J.C., Gunthorpe M.J., Brough S.J., Ranson J., Cairns W., Hayes P.D., Randall A.D., Davis J.B. Characterisation using FLIPR of human vanilloid VR1 receptor pharmacology. Eur. J. Pharmacol. 417:2001;51-58.
142. Smith P.J.W., McQueen D.S. Anandamide induces cardiovascular and respiratory reflexes via vasosensory nerves in the anaesthetized rat. Br. J. Pharmacol. 134:2001;655-663.
143. Spicuzza L., Haddad E.-B., Birrell M., Ling A., Clarke D., Venkatesan P., Barnes P.J., Belvisi M.G. Characterization of the effects of cannabinoids on guinea-pig tracheal smooth muscle tone: role in the modulation of acetylcholine release from parasympathetic nerves. Br. J. Pharmacol. 130:2000;1720-1726.
144. Sprague J., Harrison C., Rowbotham D.J., Smart D., Lambert D.G. Temperature-dependent activation of recombinant rat vanilloid VR1 receptors expressed in HEK293 cells by capsaicin and anandamide. Eur. J. Pharmacol. 423:2001;121-125.
145. Stefano G.B., Salzet B., Rialas C.M., Pope M., Kustka A., Neenan K., Pryor S., Salzet M. Morphine- and anandamide-stimulated nitric oxide production inhibits presynaptic dopamine release. Brain Res. 763:1997;63-68.
146. Stein E.A., Fuller S.A., Edgemond W.S., Campbell W.B. Physiological and behavioural effects of the endogenous cannabinoid, arachidonylethanolamide (anandamide), in the rat. Br. J. Pharmacol. 119:1996;107-114.
147. Stella N., Piomelli D. Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur. J. Pharmacol. 425:2001;189-196.
148. Storr M., Gaffal E., Saur D., Schusdziarra V., Allescher H.D. Effect of cannabinoids on neural transmission in rat gastric fundus. Can. J. Physiol. Pharm. 80:2002;67-76.
149. Szabo B., Nordheim U., Niederhoffer N. Effects of cannabinoids on sympathetic and parasympathetic neuroeffector transmission in the rabbit heart. J. Pharmacol. Exp. Ther. 297:2001;819-826.
150. Szallasi A., Blumberg P.M. Vanilloid (capsaicin) receptors and mechanisms. Pharmacol. Rev. 51:1999;159-211.
151. Szoke E., Balla Z., Csernoch L., Czeh G., Szolcsanyi J. Interacting effects of capsaicin and anandamide on intracellular calcium in sensory neurones. NeuroReport. 11:2000;1949-1952.
152. Tognetto M., Amadesi S., Harrison S., Creminon C., Trevisani M., Carreras M., Matera M., Geppetti P., Bianchi A. Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. J. Neurosci. 21:2001;1104-1109.
153. 3H-noradrenaline release by presynaptic opioid, cannabinoid and bradykinin receptors and α-adrenoceptors in mouse tissues. Br. J. Pharmacol. 130:2000;321-330.
154. 1 receptors in the rat central nervous system. Neuroscience. 83:1998;393-411.
155. Tucker R.C., Kagaya M., Page C.P., Spina D. The endogenous cannabinoid agonist, anandamide stimulates sensory nerves in guinea-pig airways. Br. J. Pharmacol. 132:2001;1127-1135.
156. Vanheel B., Van de Voorde J. Regional differences in anandamide- and methanandamide-induced membrane potential changes in rat mesenteric arteries. J. Pharmacol. Exp. Ther. 296:2001;322-328.
157. 1 cannabinoid receptor in the hypotensive action of anandamide. Eur. J. Pharmacol. 278:1995;279-283.
158. Varga K., Lake K.D., Huangfu D., Guyenet P.G., Kunos G. Mechanism of the hypotensive action of anandamide in anesthetised rats. Hypertension. 28:1996;682-686.
159. Vellani V., Mapplebeck S., Moriondo A., Davis J.B., McNaughton P.A. Protein kinase C activation potentiates gating of the vanilloid receptor VR1 by capsaicin, protons, heat and anandamide. J. Physiol. 534:2001;813-825.
160. 8-tetrahydrocannabinol-dimethylheptyl in rats. J. Cardiovasc. Pharmacol. 28:1996;332-336.
161. Von Kügelgen I., Starke K. Noradrenaline-ATP co-transmission in the sympathetic nervous system. Trends Pharmacol. Sci. 12:1991;319-324.
162. Wagner J.A., Varga K., Járai Z., Kunos G. Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension. 33:1999;429-434.
163. Walker J.M., Hohmann A.G., Martin W.J., Strangman N.M., Huang S.M., Tsou K. The neurobiology of cannabinoid analgesia. Life Sci. 65:1999;665-673.
164. Walker J.M., Krey J.F., Chu C.J., Huang S.M. Endocannabinoid and related fatty acid derivatives in pain modulation. Chem. Phys. Lipids. 121:2002;159-172.
165. Wardle K.A., Furey G., Sanger G.J. Pharmacological characterization of the vanilloid receptor in the rat isolated vas deferens. J. Pharm. Pharmacol. 48:1996;285-291.
166. White R., Ho W.-S.V., Bottrill F.E., Ford W.R., Hiley C.R. Mechanisms of anandamide-induced vasorelaxation in rat isolated coronary arteries. Br. J. Pharmacol. 134:2001;921-929.
167. Wilson R.I., Nicoll R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature. 410:2001;588-592.
168. Wilson R.I., Nicoll R.A. Endocannabinoid signaling in the brain. Science. 296:2002;678-682.
169. 1 receptor mediates retrograde signals for depolarization-induced suppression of inhibition in cerebellar purkinje cells. J. Neurosci. 22:2002;1690-1697.
170. Yousif M.H., Oriowo M.A. Inhibitory effects of cannabinoid receptor ligands on electrically-evoked responses in rat isolated tracheal ring segments. Pharmacol. Res. 40:1999;415-421.
171. Zhou X.F., Livett B.G. Capsaicin-sensitive sensory neurons are involved in the plasma catecholamine response to selective stressors. J. Physiol. 433:1991;393-407.
172. Ziganshin A.U., Ralevic V., Burnstock G. Contractility of urinary bladder and vas deferens after sensory denervation by capsaicin treatment of newborn rats. Br. J. Pharmacol. 114:1995;166-170.
173. 2 cannabinoid receptor-independent mechanism. J. Neuroscience. 22:2002;4720-4727.
174. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sørgård M., Di Marzo V., Julius D., Högestätt E.D. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 400:1999;452-457.